Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Derivatives in LYEL
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$82,246
PutShares
4,100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026DIADEMA PARTNERS LP holds $177,237,458 across 73 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
525,181 | $17,089,389 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
322,764 | $12,423,186 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
54,755 | $10,351,432 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
|
181,752 | $9,581,965 | |
| 5 | ABVX |
Abivax S.A.
|
75,944 | $8,456,364 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
148,229 | $8,373,456 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
80,872 | $7,864,802 | |
| 8 | KOD |
Kodiak Sciences Inc.
|
192,962 | $7,355,711 |
All Filings in LYEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $82,246 | 4,100 | Put | Sole | 2026-05-15 | |
| 2025-12-31 | $116,964 | 3,800 | Put | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||